On April 30, 2021, the U.S. District Court for the District of Puerto Rico
entered judgment dismissing with prejudice all claims brought against Pharma-Bio
Serv, Inc. (the "Company") and the Company's wholly-owned subsidiary, Pharma-Bio
Serv PR, Inc., ("Pharma PR") as previously disclosed in the Company's Quarterly
Report on Form 10-Q for the period ended January 31, 2021, which was filed on
March 17, 2021. In connection with the dismissal, plaintiff agreed not to file
separate claims against the officers or directors of the Company or Pharma PR.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
PHARMA-BIO SERV, INC. 
